This inventor holds 9 USPTO granted patents and 4 published patent applications and 7 EPO patents. Top assignees: Wista Laboratories Ltd., Genting Taurx Diagnostic Centre Sdn Bhd. Active years: 2020-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
7 out of 59 
2 out of 2 Years Active: 2020-2025
Title: The Innovations of Bjorn Olaf Schelter
Introduction
Bjorn Olaf Schelter is a notable inventor based in Aberdeen, GB. He has made significant contributions to the field of neurodegenerative disorder treatments, holding a total of 9 patents. His work focuses on optimizing dosage regimens for specific compounds that can enhance therapeutic efficacy.
Latest Patents
One of his latest patents is titled "Optimised dosage of diaminophenothiazines in populations." This invention provides novel dosing regimens for Leuco-Methylthioninium (LMT) compounds. The goal is to maximize the proportion of subjects in which the MT concentration will exceed levels necessary for therapeutic efficacy in treating neurodegenerative disorders such as Alzheimer's disease and frontotemporal dementias. The invention also includes LMT-containing dosage units and other compositions. Another significant patent is "Administration and dosage of diaminophenothiazines." This invention outlines novel regimens for treating neurodegenerative disorders using methylthioninium (MT)-containing compounds. These regimens are based on new findings regarding the dosage of MT compounds and their interaction with symptomatic treatments that modulate acetylcholinesterase levels.
Career Highlights
Bjorn Olaf Schelter is associated with Wista Laboratories Ltd., where he continues to innovate in the field of medical treatments. His work has the potential to significantly impact the lives of individuals suffering from neurodegenerative diseases.
Collaborations
He has collaborated with notable individuals in his field, including Claude Michel Wischik and Damon Jude Wischik. Their combined expertise contributes to the advancement of research and development in neurodegenerative disorder treatments.
Conclusion
Bjorn Olaf Schelter's contributions to the field of neurodegenerative disorder treatments through his innovative patents highlight his dedication to improving patient outcomes. His work continues to pave the way for advancements in medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile